Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Healthcare
Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(48)
•••
Comment by ChiefBroncoon Mar 02, 2020 12:37am
47 Views
Post# 30754392

RE:RE:RE:Only one person don't believe in Kalytera

RE:RE:RE:Only one person don't believe in Kalytera
ChiefBronco wrote:
ChiefBronco wrote:
ChiefBronco wrote: And he is actively trying to tell investors to bail, but it's funny nobody listen to him/her. This poster have shown me that he has serious mental problem, posting the same things hundreds of time. This tells me that something big is coming and this person is trying to scare people away, but why ? If this was true he would be the last one to tell us as he looks like a very bad person, so why tell us some lies ? ..... Easy this subject want your shares, he is a greedy s.o.b picking up all cheap shares from weak investors. It's were you see this person is very hypocrite, creating lies to scare people and get what he wants. I personally know people like him and there real A Holes and karma always catch up to these people. So no he won't get my shares as I'm holding for profits.. there are no guarantee but this is a no Brainer for sure.....  Kalytera therapeutics have very valuable patents and soon will have very valuable FDA aproved drugs, so you be the judge... I'm all in and not even nervous. Cheers to beers and good looking rears... 






Bullboard Posts
Dealroom for high-potential pre-IPO opportunities